Cipla partners with MNCs to strengthen anti-diabetes innovative portfolio: GlobalData
Cipla has recently signed an agreement to make and market the diabetes therapy Galvus and its combination brands in India from 01 January 2026.
Cipla has recently signed an agreement to make and market the diabetes therapy Galvus and its combination brands in India from 01 January 2026.
The company has posted net profit of Rs.464.4 crores for the Financial Year ended March 31, 2023
The business and product range of Ipca and that of Unichem complements each others business and product range
New high-tech facility in Biberach offers attractive workplaces for more than 500 scientists
Biocon Biologics Limited will have access to 100 million doses of vaccines annually together with the distribution rights to Serum's Vaccine portfolio
Enabling clinical effectiveness via a fully interoperable and integrated digital pathology solution
The burden of treating chronic wounds is growing rapidly due to increasing health care costs
The interaction with key Government Officials and industry leaders led to a joint exploration of possible collaboration and investments in the Healthcare ecosystem between the two countries
With a focus on optimizing patient experience with next-generation oral dosage forms, the US facility complements the cutting-edge research activities of Roquette’s existing pharma innovation centers in France and Singapore
SÜDPACK is setting standards in terms of both performance and sustainability
Subscribe To Our Newsletter & Stay Updated